Cay Hy Thiem (Siegesbeckia orientalis): Benefits, Dosage, Safety & Evidence

Questions fréquentes

How does Cay Hy Thiem work for joint pain?

Cay Hy Thiem (Siegesbeckia orientalis) contains active compounds such as kirenol and darutoside, which are believed to provide anti-inflammatory and analgesic effects. These compounds may help modulate inflammatory pathways and inhibit specific cytokines responsible for joint swelling. While traditional use supports its efficacy for arthritis, current scientific evidence is limited (Evidence Level C), and the precise molecular mechanism requires further clinical investigation.

Does Cay Hy Thiem interact with blood pressure medications?

Cay Hy Thiem is traditionally used to treat hypertension, suggesting it may lower blood pressure. Consequently, taking it alongside antihypertensive drugs could cause additive effects, potentially leading to hypotension (blood pressure that is too low). Patients on blood pressure medication should consult a healthcare provider before use to monitor for interactions, as specific clinical drug-interaction studies are lacking (Evidence Level C).

What is the standard dosage for Cay Hy Thiem?

The typical adult dosage for Cay Hy Thiem is 9 to 15 grams of the dried herb per day. It is commonly prepared as a decoction or tea. Dosage may vary based on individual needs and the specific condition being addressed, such as joint pain or skin inflammation. Users should adhere to guidance from a qualified healthcare practitioner (Traditional use).

Is Cay Hy Thiem safe to use during pregnancy?

No, Cay Hy Thiem is considered unsafe during pregnancy. Due to a lack of safety data and potential risks suggested by traditional use, pregnant women should avoid this herb. It is also advisable for breastfeeding women to avoid use due to insufficient safety information. Always seek professional medical advice regarding herbal supplementation during pregnancy (Evidence Level C).

What are the side effects of Cay Hy Thiem?

Cay Hy Thiem is generally well tolerated when taken at recommended dosages. Reported side effects are minimal, though specific clinical trial data regarding adverse events is limited. As with any herbal supplement, individual allergic reactions are possible. Users should discontinue use if they experience any unexpected symptoms and consult a healthcare provider (Evidence Level C).

Fiche d'information compilée à partir de PubMed

Cette fiche a été compilée à partir de résumés PubMed (NIH) avec l'assistance d'une IA. Chaque affirmation factuelle est citée par un article PubMed réel (voir la liste des sources). Elle n'a pas encore été révisée par un humain — confirmez auprès d'un professionnel de santé avant utilisation.

Compilé à partir de 30 articles PubMed · modèle : gemma4:31b

Résumé

Siegesbeckia orientalis is a medicinal herb used traditionally for inflammatory diseases and stroke [PMID: 40289983], demonstrating potential neuroprotective, anti-inflammatory, and anti-cancer activities in preclinical models [PMID: 39986221, 27527140].

Contexte

Siegesbeckia orientalis L. is an annual herb widely distributed globally and is a primary source of Sigesbeckiae Herba [PMID: 29334256, 39986221]. It is recognized as a cadmium-hyperaccumulator capable of phytoremediation [PMID: 32207009].

Usages traditionnels

Traditionally used in Chinese medicine for inflammatory diseases and stroke [PMID: 40289983], and in Vietnam for the treatment of acute arthritis, rheumatism, and gout [PMID: 28376775]. It has also been used as a topical anti-inflammatory and analgesic agent [PMID: 21798328].

Composés actifs

Key active components include kirenol [PMID: 31730422, 42235317], ent-pimarane-type diterpenoids such as darutigenol, darutoside, and hythiemoside A and B [PMID: 15684525], ent-kaurane diterpenoids [PMID: 41207692], guaianolide sesquiterpenes, and benzoate esters [PMID: 34329938]. It also contains phenolic and flavonoid compounds [PMID: 29065451].

Mécanisme d'action

The herb exerts neuroprotection by reversing the pro-inflammatory status of microglia [PMID: 40289983] and impeding RAGE-CD11b interaction driven by HMGB1 to reduce neutrophil-involved neuronal injury [PMID: 39986221]. It inhibits inflammation by blocking NF-κB activation via the prevention of IκB-α degradation [PMID: 25328884]. Other mechanisms include stimulating mitochondrial biogenesis via the AMPK/SIRT1/PGC-1α pathway to increase exercise endurance [PMID: 31730422], inhibiting adipogenesis through the Wnt/β-catenin signaling pathway [PMID: 32582460], and suppressing TYK2 to alleviate atopic dermatitis [PMID: 42235317].

Preuves cliniques

Preuve DIschemic Stroke (Murine)

Ethanol extract alleviated neutrophil-involved neuronal injury and reduced microglia-related inflammatory injury [PMID: 39986221, 40289983]

Preuve DEndometrial Cancer (In vitro)

Ethanol extract inhibited migration, invasion, and proliferation of RL95-2 and HEC-1A cells by reversing TGFβ1-induced epithelial-mesenchymal transition and inducing apoptosis [PMID: 27527140, 25470271]

Preuve DRheumatoid Arthritis

Demonstrated therapeutic effects through network pharmacology and experimental validation [PMID: 37390879]

Preuve DExercise Endurance (Mice)

Standardized extract increased running distance and time by stimulating mitochondrial biogenesis [PMID: 31730422]

Preuve DAtopic Dermatitis

Kirenol alleviates symptoms by suppressing TYK2 [PMID: 42235317]

Preuve DHyperuricemia (Rats)

Crude ethanol extract and n-butanol-soluble fraction showed anti-hyperuricemic and anti-inflammatory effects [PMID: 28376775]

Synthèse des preuves

The current evidence is based primarily on in vitro studies and animal models (Level D), demonstrating strong anti-inflammatory and neuroprotective potential, though human clinical trials are lacking in the provided data.

Sources PubMed

1.PMID: 39986221 (2025) — Siegesbeckia orientalis ethanol extract impedes RAGE-CD11b interaction driven by HMGB1 to alleviate neutrophil-involved neuronal injury poststroke. · Phytomedicine : international journal of phytotherapy and phytopharmacology
2.PMID: 40289983 (2025) — The Extract of Siegesbeckia orientalis L. Reverses Pro-inflammatory Status of Microglia for Neuroprotection Following Ischemic Stroke in Mice. · Current neuropharmacology
3.PMID: 37035082 (2023) — Activation and tolerance of Siegesbeckia Orientalis L. rhizosphere to Cd stress. · Frontiers in plant science
4.PMID: 27527140 (2016) — Siegesbeckia orientalis Extract Inhibits TGFβ1-Induced Migration and Invasion of Endometrial Cancer Cells. · Molecules (Basel, Switzerland)
5.PMID: 37390879 (2023) — Therapeutic effects of Siegesbeckia orientalis L. and its active compound luteolin in rheumatoid arthritis: network pharmacology, molecular docking and experimental validation.

Cay Hy Thiem

Sources et citations

Calculer une dose sûre de Cay Hy Thiem